Teva has penned a second pact with Royalty Pharma, this time securing up to $500 million to support the clinical development ...

Kim Kardashian revealed this week that one of her two sons -- Saint, 8, or Psalm, 5 -- has the rare skin condition vitiligo. Kim Kardashian, 43, revealed this week that one of her two sons — Saint, 8, ...

Vitiligo is associated with increased cardiovascular disease risk, affecting organ function and metabolic syndrome. A large-scale US study found 54 cardiovascular diseases with increased risk in ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an ...

New study reveals higher cardiovascular risk in vitiligo patients, underscoring need for proactive care. Study: Vitiligo is associated with an increased risk of cardiovascular diseases: a large-scale, ...

Teva Pharmaceuticals TEVA announced a funding agreement with Royalty Pharma plc RPRX, under which the latter will provide up to $500 million to accelerate the development of Teva’s anti-IL-15 antibody ...

Royalty Pharma and the US affiliate of Israel’s Teva Pharmaceutical Industries have announced a funding agreement of up to ...

The burden of vitiligo in the United States is poorly understood. To investigate the incidence and prevalence of diagnosed vitiligo in the United States, the researchers used a 15% random sample of ...

Israeli patients with vitiligo exhibit a significantly reduced risk of developing Parkinson disease (PD). This large-scale population-based study included 2 different designs. One was a retrospective ...

Kim Kardashian has long been open about her experience with psoriasis, often sharing unfiltered looks at her outbreaks on social media and explaining how the skin condition has impacted her life. On a ...

While discussing her psoriasis journey on Monday’s episode of the “She MD” podcast, Kardashian explained that vitiligo, which causes patches of skin to lose pigment or color, can be hereditary. “It ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 ...